Ventilator-Associated Pneumonia

VAP: Definition & Epidemiology - Lungs Under Siege

• Pneumonia developing >48 hours after endotracheal intubation.
• Most frequent ICU-acquired infection in mechanically ventilated (MV) patients.
• Affects 9-27% of intubated individuals; ↑ morbidity & mortality.
• Types based on onset:
  • Early-onset VAP (EOVAP): <5 days of intubation.
    • Usually antibiotic-sensitive bacteria (e.g., S. pneumoniae, MSSA).
  • Late-onset VAP (LOVAP): ≥5 days of intubation.
    • Often MDR pathogens (e.g., P. aeruginosa, MRSA, Acinetobacter spp.).

⭐ LOVAP: ↑ risk of inadequate initial antibiotics & worse outcomes.

VAP: Pathogenesis & Etiology - How Bugs Sneak In

• Pathogenesis:
  • Primary: Microaspiration of secretions (oropharyngeal, gastric) past ET tube cuff.
  • Biofilm formation on ET tube: Protects bacteria, promotes resistance.
  • Others: Contaminated aerosols, rarely hematogenous.

• Etiology:

  Onset Type	Timing	Common Pathogens
  Early-onset VAP	<5 days	S. pneumoniae, H. influenzae, MSSA, antibiotic-sensitive Enterobacteriaceae.
  Late-onset VAP	≥5 days	P. aeruginosa, Acinetobacter spp., MRSA, ESBL-producing GNBs (often MDR).

• Key Risk Factors: Prolonged ventilation, supine positioning, prior antibiotic use, advanced age, stress ulcer prophylaxis (PPIs/H2 blockers).

⭐ Biofilms on endotracheal tubes are a critical factor for VAP development, especially with MDR organisms in late-onset cases.

VAP: Diagnosis - Finding the Foe

• New/progressive lung infiltrate on CXR + ≥2 clinical signs (fever >38°C, leukocytosis/leukopenia, purulent secretions).
• Clinical Pulmonary Infection Score (CPIS): Score >6 suggests VAP.

  Component	Points
  Temperature	0-2
  WBC Count	0-2
  Tracheal Secretions	0-2
  Oxygenation (PaO2/FiO2)	0-2
  CXR Infiltrate	0-2
  Tracheal Aspirate Culture	0-2

• Microbiological confirmation (quantitative cultures preferred):
  • Endotracheal Aspirate (ETA): ≥10⁵ CFU/mL
  • Bronchoalveolar Lavage (BAL): ≥10⁴ CFU/mL
  • Protected Specimen Brush (PSB): ≥10³ CFU/mL
• 
• Diagnostic Algorithm:

(*Fever, ↑WBC, Purulent Secretions)

⭐ Quantitative cultures of lower respiratory tract samples are preferred over qualitative cultures for VAP diagnosis to reduce inappropriate antibiotic use.

VAP: Management - Fighting Back Smart

• Initiate empiric antibiotics promptly (within 1 hour of suspicion).
• Base choice on MDR risk factors & local antibiogram.
• De-escalate therapy based on culture results.
• Typical duration: 7 days.

⭐ Quantitative cultures (e.g., BAL >10,000 CFU/mL, PSB >1,000 CFU/mL) preferred to guide VAP therapy.

VAP: Prevention - Keeping Lungs Clear

VAP prevention focuses on meticulous care bundles. Key elements:

• Head of bed (HOB) elevation: 30-45 degrees continuously.
• Daily sedation interruption ("sedation vacation") & readiness-to-extubate assessment.
• Thorough oral care with chlorhexidine (e.g., 0.12% solution q6-12h).
• Stress ulcer (PUD) prophylaxis.
• Venous thromboembolism (DVT) prophylaxis.
• Maintain endotracheal tube cuff pressure at 20-30 $cm H_2O$.
• Use subglottic secretion drainage (SSD) tubes where possible.

⭐ Consistent application of VAP bundles can decrease VAP rates by over 50%.

High‑Yield Points - ⚡ Biggest Takeaways

• VAP: Pneumonia developing >48 hours post-intubation and mechanical ventilation.
• Common pathogens: P. aeruginosa, Acinetobacter, MRSA, ESBL-producing Enterobacteriaceae.
• Late-onset VAP (≥5 days) strongly associated with MDR organisms.
• Diagnosis: New radiographic infiltrate with clinical signs (fever, purulent sputum) & microbiology.
• Prevention: Key is the VAP bundle (head elevation 30-45°, oral chlorhexidine, sedation holds).
• Treatment: Empiric broad-spectrum antibiotics, then de-escalate based on cultures.